Search results
Biotech faces a reckoning: 'We've lost our luster in cell therapies'
FierceBiotech· 7 days agoThis story is part one in a four-part series about cell therapy created by the Fierce Biotech team....
Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology
FierceBiotech· 6 days agoThis story is part 2 in a four-part series about cell therapy created by the Fierce Biotech team....
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC
MedPage Today· 3 days agoEGFR testing now needed for all patients with stage III disease, experts say
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML
MedPage Today· 5 days agoThe STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with...
No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC
MedPage Today· 3 days agoResults are 'disappointing as we need better therapies in the refractory space,' expert says
Triplet Notches Survival Win in Heavily Pretreated DLBCL
MedPage Today· 3 days agoBenefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant
Is Nvidia Worth 35x Times Sales? History Says No
Investing.com· 7 days agoYou wouldn’t be able to tell just by looking at the S&P 500 daily change of +0.02%, but yesterday was a pretty negative day, with the S&P 500 Equal...